In the ever-evolving landscape of hepatocellular carcinoma (HCC) treatment, every breakthrough brings us closer to improving patient outcomes. We are thrilled to present an exclusive interview with Professor Andrea Casadei-Gardini, a leading expert in oncology, who shares pivotal findings from his recent paper, “Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.”
Key Highlights from the Study
Prof. Casadei-Gardini’s retrospective study sheds light on the effectiveness of second-line therapies in patients whose advanced HCC has progressed following first-line treatment with atezolizumab and bevacizumab. Here are some key findings:
- Improved Survival with Lenvatinib: Patients receiving lenvatinib as a second-line treatment achieved a median overall survival (mOS) of 18.9 months, significantly longer than the 14.3 months observed with sorafenib (HR: 2.24, p=0.01).
- Positive Prognostic Factors: The study identified lenvatinib therapy and albumin-bilirubin grade 1 as strong predictors of overall survival.
- Real-World Evidence: This study bridges the gap between clinical trials and actual practice, offering valuable insights for oncologists worldwide.
Why This Matters
For many countries, sorafenib remains the standard second-line therapy due to reimbursement challenges. Prof. Casadei-Gardini’s findings could catalyze a shift in treatment paradigms, advocating for lenvatinib as a viable and potentially superior alternative in certain cases.
Don’t Miss the Interview
Dive deeper into this groundbreaking research in our engaging interview, where Prof. Casadei-Gardini discusses:
- The motivation behind the study.
- Challenges in real-world oncology research.
- The implications of these findings for clinical practice.
Watch the Full Intervie here
Join the Conversation
We invite oncologists, hepatologists, and all specialists in liver cancer management to watch this insightful interview and share your perspectives. Could lenvatinib redefine the second-line treatment for HCC? Let’s discuss!